In OPTIMA prelim trial which compared multiparameter tests in patients with ER+/HER2‐, early‐stage breast cancer, the rate of low‐risk categorized by Mammaprint and Oncotype DX was 61.4% and 54.2%, respectively.26 This evidence concerns the gene ERBB2 and breast cancer.